Suggested remit: To appraise the clinical and cost effectiveness of semaglutide 7.2 mg dose, within its marketing authorisation, in addition to a reduced calorie diet and increased physical activity, for weight management in adults.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Criteria within the 2024 Voluntary Scheme for Pricing, Access and Growth (VPAG) met as a significant licence extension. This is a higher dose than semaglutide within TA875 that looks to be a higher cost thus impacting cost effectiveness.
- Process:
- STA Standard
- ID number:
- 6699
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6699:
- 28 May 2026 - 25 June 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 May 2026 | In progress. Scoping commencing |
| 15 December 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 15 December 2025 | Topic prioritisation |
For further information on our processes and methods, please see our CHTE processes and methods manual